复方苦参注射液联合纳武利尤单抗治疗晚期非小细胞肺癌的临床研究  

Clinical study of Compound Kushen Injection combined with navulizumab in treatment of advanced non-small cell lung cancer

作　　者：刘莎 袁可淼[2] 尤建良[2] LIU Sha;YUAN Kemiao;YOU Jianliang(Department of Clinical Nutrition,Wuxi Hospital of Traditional Chinese Medicine,Wuxi 214000,China;Department of Oncology,Wuxi Hospital of Traditional Chinese Medicine,Wuxi 214000,China)

机构地区：[1]无锡市中医医院临床营养科,江苏无锡214000 [2]无锡市中医医院肿瘤科,江苏无锡214000

出　　处：《现代药物与临床》2025年第1期161-165,共5页Drugs & Clinic

基　　金：国家重点计划研发项目(2018YFC1705102)。

摘　　要：目的分析复方苦参注射液联合纳武利尤单抗注射液治疗晚期非小细胞肺癌患者的临床效果。方法选取2020年1月—2021年12月无锡市中医医院收治的100例晚期非小细胞肺癌患者,根据患者的治疗方案将患者分为对照组和治疗组,每组各50例。对照组给予纳武利尤单抗注射液3 mg/kg,静脉输注60 min,2周用药1次;治疗组在对照组基础上第1~14天静脉滴注复方苦参注射液20 mL,与0.9%氯化钠注射液200 mL充分混合。21 d为1个周期,两组患者均连续治疗3个周期。比较两组的临床疗效、生活质量、肿瘤标志物水平变化、不良反应和生存情况。结果治疗组的客观缓解率、疾病控制率高于对照组(P<0.05)。治疗后,两组的Karnofsky功能状态评分标准(KPS)评分均升高(P<0.05),治疗组的KPS评分高于对照组(P<0.05)。治疗后,两组的血清细胞角蛋白19片段抗原21-1(CYFRA21-1)、神经元特异性烯醇化酶(NSE)、癌胚抗原(CEA)水平均显著降低(P<0.05),治疗组的血清CYFRA21-1、NSE、CEA水平低于对照组(P<0.05)。治疗组疲劳、胃肠道反应发生例数少于对照组(P<0.05)。治疗组的中位无进展生存期、总生存期长于对照组(P<0.05)。结论复方苦参注射液联合纳武利尤单抗注射液治疗晚期非小细胞肺癌可获得较好的临床效果,对改善生活质量、降低肿瘤标志物水平有积极作用,还可以延长患者生存时间、降低不良反应。Objective To analyze the clinical efficacy of Compound Kushen Injection combined with Navolizumab Injection in treatment of advanced non-small cell lung cancer.Methods 100 Patients with advanced non-small cell lung cancer admitted to Wuxi Hospital of Traditional Chinese Medicine from January 2020 to December 2021.Patients were divided into control group and treatment group based on their different treatment plans,with 50 patients in each group.Patients in the control group were given Navulizumab Injection 3 mg/kg,intravenous infusion for 60 min,once every 2 weeks.Patients in the treatment group were iv administered with 20 mL Compound Kushen Injection on the basis of the control group,from first day to 14th day,which was thoroughly mixed with 200 mL 0.9%sodium chloride injection.One course had 21 days,and both groups of patients were treated continuously for three courses.The clinical efficacy,quality of life,changes in tumor marker levels,adverse reactions,and survival status were compared between two groups.Results The objective remission rate and disease control rate of the treatment group were higher than those of the control group(P<0.05).After treatment,KPS scores of both groups were significantly increased(P<0.05),and KPS scores of the treatment group were higher than those of the control group(P<0.05).After treatment,the levels of serum CYFRA21-1,NSE,and CEA in both groups were significantly reduced(P<0.05),and the serum levels of CYFRA21-1,NSE,and CEA in the treatment group were lower than those in the control group(P<0.05).The incidence of fatigue and gastrointestinal reactions in the treatment group was lower than that in the control group(P<0.05).The median progression free survival and overall survival of the treatment group were longer than those of the control group(P<0.05).Conclusion The combination of Compound Kushen Injection and Navulizumab Injection can achieve good clinical effects in treatment of advanced non-small cell lung cancer,which has a positive effect on improving quality of life,red

关 键 词：复方苦参注射液 纳武利尤单抗注射液 晚期非小细胞肺癌 KPS评分 细胞角蛋白19片段抗原21-1 神经元特异性烯醇化酶 癌胚抗原 中位无进展生存期 总生存期 

分 类 号：R979.1[医药卫生—药品]